Zimmer Biomet Holdings, Inc.
NYSEZimmer Biomet heads into its August 5 earnings report with the analyst community suddenly more divided — and a fresh upgrade from a major bank reshaping the debate just days before the print. UBS moved to Buy on July 28, lifting its target from $89 to $115 — a swing of nearly $26 and a complete reversal from a prior Sell rating. That's the sharpest single move in the recent analyst…
ZBH short interest surges 28.8% in one week to 6.0% of float, driven by rising bearish positioning in medical devices.
Zimmer Biomet heads into its August 5 earnings report with the analyst community suddenly more divided — and a fresh upgrade from a major bank reshaping the debate just days before the print. UBS moved to Buy on July…
Zimmer Biomet heads into its July 28 earnings report carrying one of the more interesting short-interest setups in MedTech — a third more short exposure than a month ago, yet with a stock that has quietly…
Snapshot as of 6 Aug 2026
Zimmer Biomet Holdings reports Q1 2026 results on May 22 carrying the fresh bruise of a 13% one-day drop from its prior quarterly print — and options traders are already moving for cover. The clearest signal heading…
ZBH enters its May 6 earnings call having just absorbed a wave of coordinated analyst target cuts — a rare pre-print repricing that sets up one of the more charged setups the orthopedic giant has seen in years. The…
Short interest in Zimmer Biomet has jumped 35% over the past month to 5.2% of the float ahead of Monday's earnings print. Analysts remain divided with 17 hold ratings and no clear consensus target, while options…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ZBH — free to start on ORTEX.
Sign up for free →Open ZBH on ORTEX